Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 5 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 5 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 5 months ago STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal - 6 months ago STAT+: Texas AG accuses Pfizer of ‘intentionally’ overstating Covid-19 vaccine effectiveness - 6 months ago STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without - 6 months ago STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge - 6 months ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - 6 months ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - 6 months ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - 6 months ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - 7 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 7 months ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - 7 months ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - 7 months ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - 7 months ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - 8 months ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - 8 months ago
2	Rich Smith Motley Fool Wealth management journalist. New York, New York brokeragesRIAsracial equityregulationcompliance	Why Pfizer Stock Is Bouncing Back - 5 months ago
3	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	Merck's 21-Valent Pneumococcal Conjugate Vaccine Granted FDA Priority Review - 5 months ago Pfizer Clears Final Regulatory Hurdles to Acquire Seagen Inc - 5 months ago
4	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	FDA chastens pet companies over antibiotics - 5 months ago Johnson & Johnson bets heavy on AI-driven drug discovery - 6 months ago Johnson & Johnson antiviral pill for dengue shows early efficacy - 7 months ago
5	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Is it time to worry about Moderna? - 5 months ago STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs; Merck buys a neuro startup - 6 months ago Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro - 7 months ago
6	Keith Speights Motley Fool Investor, author, Motley Fool contributor. investingwriting	Why Pfizer Stock Is Sinking Today - 5 months ago Why Pfizer Stock Is Sinking Today - 6 months ago
7	https://www.facebook.com/lisa.stiffler.5 GeekWire	Pfizer wins regulatory approval for its $43B acquisition of Seattle-area biotech giant Seagen - 5 months ago
8	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors - 5 months ago Pfizer Just Announced Layoffs. Should You Still Buy the Stock? - 7 months ago Pfizer Stock: Bear vs. Bull - 8 months ago
9	David Jagielski Motley Fool	Is Pfizer Stock a Buy Now? - 5 months ago Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant - 6 months ago
10	Rachel Cohrs STAT News Washington Correspondent @statnews. Washington, DC health policyjournalism	STAT+: Pfizer plans to depart BIO - 5 months ago

Journalists covering Pfizer